购物车
您的购物车当前为空
BMS CCR2 22 是一种有效的选择性 CC 型趋化因子受体2拮抗剂,钙通量 IC50为 18 nM,趋化性 IC50为1 nM,结合 IC50为5.1 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
BMS CCR2 22 是一种有效的选择性 CC 型趋化因子受体2拮抗剂,钙通量 IC50为 18 nM,趋化性 IC50为1 nM,结合 IC50为5.1 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 778 | 现货 | |
| 5 mg | ¥ 1,550 | 现货 | |
| 10 mg | ¥ 2,180 | 现货 | |
| 25 mg | ¥ 3,690 | 现货 | |
| 50 mg | ¥ 4,880 | 现货 | |
| 100 mg | ¥ 6,770 | 现货 | |
| 200 mg | ¥ 9,130 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 2,270 | 现货 |
| 产品描述 | BMS CCR2 22 is a potent and selective antagonist of CCR2 with calcium flux IC50 of 18 nM, chemotaxis IC50 of 1 nM, and binding IC50 of 5.1 nM. |
| 靶点活性 | CCR2:5.1 nM |
| 体外活性 | BMS CCR2 22 inhibits the internalization of hMCP1_AF647 (IC50 = 2 nM)[2]. HAoECs with BMS CCR2 22 before MCP-1 increases the cell surface levels of VCAM-1 from 72.8 to 160% and PECAM1 from 97.2 and 127%[3]. |
| 分子量 | 593.66 |
| 分子式 | C28H34F3N5O4S |
| CAS No. | 445479-97-0 |
| Smiles | CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F |
| 密度 | 1.33 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 225 mg/mL (379 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+90% Corn Oil: 3.3 mg/mL (5.56 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多